Thrilled to present this phase 1 of lefitolimod (TLR9 agonist) plus ipilimimab in refractory advanced tumors. It was safe and well tolerated and we expect maybe other combinations will improve the efficacy! Why not anti-PD1/L1? David S. Hong MD JIPO Editors

DESTINY-PANTumor-02 results were just presented at #ASCO23: T-DXd shows broad activity across tumor types, including gyn cancers, with a toxicity profile consistent with previous studies: fal.cn/3yPdP #ASCODailyNews MD Anderson Cancer Center #gyncsm

🤯Exciting data for GYN Cancer | #GYNCSM presented at #ASCO23 DT session by MD Anderson Cancer Center Dr. Funda Meric-Bernstam! 🎯DESTINY Pan-Cancer demonstrated activity of T-DXd (#AntibodyDrugConjugate) across multiple #HER2 ➕tumors 👍especially #EndometrialCancer #CervicalCancer & #OvarianCancer

📣📣METcount matters! Privileged to present MET-driven 🎯NCI MATCH subprotocols with genomic analysis at #ASCO2023 this year, supported by ⭐️ mentor David S. Hong MD We show that in METex14 tumors, identifying true PVs by METcount quantification is impactful MD Anderson Cancer Center NIH

One of the greatest joys of mentorship is seeing your trainees soar! Meet Niamh Coleman, MD PhD Rising star 🌟 & amazing oncologist in Ireland 🇮🇪 Thrilled to work with Dr. coleman in the #PrecisionMedicine working group ESMO - Eur. Oncology cc Ben Westphalen Jarushka Naidoo

🚨Hot off the press 👉Delighted to share before end of 2023 our investigator initiated study that was just published in AACR Journal Cancer Research Communications 👉"Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations

#ASCO24 Day 2 - great to see our EMITT-1 trial of novel ERAP1 inhibitor first in class poster presented at ASCO, and meet fellow #ESMO25 tumor agnostic track committee member Niamh Coleman, MD PhD 🇮🇪 finally in person! 💚💜

Great to be at #ASCO24 to present our work on rare BRAF non-V600 variants Grateful for collaboration &mentorship Vivek Subbiah, MD 📣 BRAF fusions + non-V600 missense mutations are pan cancer targets 🎯 Most are oncogenic drivers 🎯 Urgent drug development needed Trinity St James's Cancer Institute

Birds of the Early Phase drug development #PrecisionMedicine feather flock together ASCO Sarah Cannon Docs #ASCO24 #SCRI party 🎉

#ASCO24 Lung Orals🔥 Ph III BEAT-MESO trial ETOP IBCSG Partners Foundation of bev+chemo +/- atezo in 1L MPM: - mOS 20.5 vs 18.1m (HR 0.84, p=0.14) - mPFS 9.2 v 7.6m (HR 0.76, p=0.002) - +interaction test for histology Stately presentation by Sanjay Popat ASCO ESMO - Eur. Oncology IASLC OncoAlert #LCSM

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies onclive.com/view/dual-targ… via OncLive.com

AACR elections are here🎉 Delighted to support a great friend & PARP superstar & drug developer the one & only Dr. Tim Yap for the board position #AACRelections

Last day to vote for the AACR elections! Vote for Dr Yap even though he is a Liverpool fan!

Great to take a break from the oncology/cancer research Disneyland that is #AACR25 AACR to connect and brainstorm with the ESMO - Eur. Oncology #ESMO25 #tumoragnosticcommittee to ⬆️ 🧬💊 Looking forward to exciting projects ahead! Vivek Subbiah, MD Niamh Coleman, MD PhD Juliana Beal, MD

Louise Kelly shares her research at ASCO on sexual health communication in Young Onset Cancer. Incredible to see this vital work recognized on a global platform 👏🏼Irish Cancer Society Trinity St James's Cancer Institute Maeve Lowery Emily Harrold St James's Hospital

Congrats David O Reilly on the PLAN trial: plasma-first liquid biopsy (LB) v tissue (TB) for NSCLC in🇮🇪 EJCANCER: - 138pts - 3wk⬇️in time to genomic result,LB>TB - 90% concordance - LB half the cost (micro-cost analysis) OncoAlert Beaumont RCSI Cancer Centre #LCSM ejcancer.com/article/S0959-…

michaeltmccarthy RTÉ News HSE Ireland Prof Barry is using the art of distraction from the real issues that impact patients which is lack of access to cutting edge treatments Unfortunately the media is helping him do this without any counter argument UCAN IRELAND Fergal Bowers Morning Ireland Real issue is here👇